Eli Lilly's investigational drug olomorasib received FDA Breakthrough Therapy designation for treating advanced pancreatic cancer patients with the KRAS G12C mutation who have had prior systemic therapy. This designation aims to speed up development and review due to promising early results from a Phase 1/2 trial showing potential benefits in this hard-to-treat cancer with limited options. Olomorasib is a selective KRAS G12C inhibitor also being studied for lung cancer, highlighting its broad potential in targeting KRAS G12C-driven tumors. The drug now has two Breakthrough Therapy designations, reflecting its promise in addressing significant unmet medical needs.
Wall Street is expected to start August mostly higher with Dow Jones futures up 1% and S&P 500 gaining 0.5%, while Nasdaq futures remain flat following a recent tech rebound. Last month, technology stocks struggled, notably the Philadelphia Semicondu...
SpaceX will release its first public earnings report focusing on Starlink's growth, Starship development, and capital spending. Despite shares falling over 50% from their peak and trading below the IPO price, Wall Street remains optimistic with bulli...
As employers increasingly drop insurance coverage for GLP-1 weight-loss drugs like Wegovy and Zepbound, major retailers such as Walmart, Costco, CVS, and Amazon are expanding direct-to-consumer prescription programs to capture market share. These pro...
